Cargando…
PERK Is a Haploinsufficient Tumor Suppressor: Gene Dose Determines Tumor-Suppressive Versus Tumor Promoting Properties of PERK in Melanoma
The unfolded protein response (UPR) regulates cell fate following exposure of cells to endoplasmic reticulum stresses. PERK, a UPR protein kinase, regulates protein synthesis and while linked with cell survival, exhibits activities associated with both tumor progression and tumor suppression. For ex...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5207760/ https://www.ncbi.nlm.nih.gov/pubmed/27977682 http://dx.doi.org/10.1371/journal.pgen.1006518 |
_version_ | 1782490429972807680 |
---|---|
author | Pytel, Dariusz Gao, Yan Mackiewicz, Katarzyna Katlinskaya, Yuliya V. Staschke, Kirk A. Paredes, Maria C. G. Yoshida, Akihiro Qie, Shuo Zhang, Gao Chajewski, Olga S. Wu, Lawrence Majsterek, Ireneusz Herlyn, Meenhard Fuchs, Serge Y. Diehl, J. Alan |
author_facet | Pytel, Dariusz Gao, Yan Mackiewicz, Katarzyna Katlinskaya, Yuliya V. Staschke, Kirk A. Paredes, Maria C. G. Yoshida, Akihiro Qie, Shuo Zhang, Gao Chajewski, Olga S. Wu, Lawrence Majsterek, Ireneusz Herlyn, Meenhard Fuchs, Serge Y. Diehl, J. Alan |
author_sort | Pytel, Dariusz |
collection | PubMed |
description | The unfolded protein response (UPR) regulates cell fate following exposure of cells to endoplasmic reticulum stresses. PERK, a UPR protein kinase, regulates protein synthesis and while linked with cell survival, exhibits activities associated with both tumor progression and tumor suppression. For example, while cells lacking PERK are sensitive to UPR-dependent cell death, acute activation of PERK triggers both apoptosis and cell cycle arrest, which would be expected to contribute tumor suppressive activity. We have evaluated these activities in the BRAF-dependent melanoma and provide evidence revealing a complex role for PERK in melanoma where a 50% reduction is permissive for Braf(V600E)-dependent transformation, while complete inhibition is tumor suppressive. Consistently, PERK mutants identified in human melanoma are hypomorphic with dominant inhibitory function. Strikingly, we demonstrate that small molecule PERK inhibitors exhibit single agent efficacy against Braf(V600E)-dependent tumors highlighting the clinical value of targeting PERK. |
format | Online Article Text |
id | pubmed-5207760 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-52077602017-01-19 PERK Is a Haploinsufficient Tumor Suppressor: Gene Dose Determines Tumor-Suppressive Versus Tumor Promoting Properties of PERK in Melanoma Pytel, Dariusz Gao, Yan Mackiewicz, Katarzyna Katlinskaya, Yuliya V. Staschke, Kirk A. Paredes, Maria C. G. Yoshida, Akihiro Qie, Shuo Zhang, Gao Chajewski, Olga S. Wu, Lawrence Majsterek, Ireneusz Herlyn, Meenhard Fuchs, Serge Y. Diehl, J. Alan PLoS Genet Research Article The unfolded protein response (UPR) regulates cell fate following exposure of cells to endoplasmic reticulum stresses. PERK, a UPR protein kinase, regulates protein synthesis and while linked with cell survival, exhibits activities associated with both tumor progression and tumor suppression. For example, while cells lacking PERK are sensitive to UPR-dependent cell death, acute activation of PERK triggers both apoptosis and cell cycle arrest, which would be expected to contribute tumor suppressive activity. We have evaluated these activities in the BRAF-dependent melanoma and provide evidence revealing a complex role for PERK in melanoma where a 50% reduction is permissive for Braf(V600E)-dependent transformation, while complete inhibition is tumor suppressive. Consistently, PERK mutants identified in human melanoma are hypomorphic with dominant inhibitory function. Strikingly, we demonstrate that small molecule PERK inhibitors exhibit single agent efficacy against Braf(V600E)-dependent tumors highlighting the clinical value of targeting PERK. Public Library of Science 2016-12-15 /pmc/articles/PMC5207760/ /pubmed/27977682 http://dx.doi.org/10.1371/journal.pgen.1006518 Text en © 2016 Pytel et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Pytel, Dariusz Gao, Yan Mackiewicz, Katarzyna Katlinskaya, Yuliya V. Staschke, Kirk A. Paredes, Maria C. G. Yoshida, Akihiro Qie, Shuo Zhang, Gao Chajewski, Olga S. Wu, Lawrence Majsterek, Ireneusz Herlyn, Meenhard Fuchs, Serge Y. Diehl, J. Alan PERK Is a Haploinsufficient Tumor Suppressor: Gene Dose Determines Tumor-Suppressive Versus Tumor Promoting Properties of PERK in Melanoma |
title | PERK Is a Haploinsufficient Tumor Suppressor: Gene Dose Determines Tumor-Suppressive Versus Tumor Promoting Properties of PERK in Melanoma |
title_full | PERK Is a Haploinsufficient Tumor Suppressor: Gene Dose Determines Tumor-Suppressive Versus Tumor Promoting Properties of PERK in Melanoma |
title_fullStr | PERK Is a Haploinsufficient Tumor Suppressor: Gene Dose Determines Tumor-Suppressive Versus Tumor Promoting Properties of PERK in Melanoma |
title_full_unstemmed | PERK Is a Haploinsufficient Tumor Suppressor: Gene Dose Determines Tumor-Suppressive Versus Tumor Promoting Properties of PERK in Melanoma |
title_short | PERK Is a Haploinsufficient Tumor Suppressor: Gene Dose Determines Tumor-Suppressive Versus Tumor Promoting Properties of PERK in Melanoma |
title_sort | perk is a haploinsufficient tumor suppressor: gene dose determines tumor-suppressive versus tumor promoting properties of perk in melanoma |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5207760/ https://www.ncbi.nlm.nih.gov/pubmed/27977682 http://dx.doi.org/10.1371/journal.pgen.1006518 |
work_keys_str_mv | AT pyteldariusz perkisahaploinsufficienttumorsuppressorgenedosedeterminestumorsuppressiveversustumorpromotingpropertiesofperkinmelanoma AT gaoyan perkisahaploinsufficienttumorsuppressorgenedosedeterminestumorsuppressiveversustumorpromotingpropertiesofperkinmelanoma AT mackiewiczkatarzyna perkisahaploinsufficienttumorsuppressorgenedosedeterminestumorsuppressiveversustumorpromotingpropertiesofperkinmelanoma AT katlinskayayuliyav perkisahaploinsufficienttumorsuppressorgenedosedeterminestumorsuppressiveversustumorpromotingpropertiesofperkinmelanoma AT staschkekirka perkisahaploinsufficienttumorsuppressorgenedosedeterminestumorsuppressiveversustumorpromotingpropertiesofperkinmelanoma AT paredesmariacg perkisahaploinsufficienttumorsuppressorgenedosedeterminestumorsuppressiveversustumorpromotingpropertiesofperkinmelanoma AT yoshidaakihiro perkisahaploinsufficienttumorsuppressorgenedosedeterminestumorsuppressiveversustumorpromotingpropertiesofperkinmelanoma AT qieshuo perkisahaploinsufficienttumorsuppressorgenedosedeterminestumorsuppressiveversustumorpromotingpropertiesofperkinmelanoma AT zhanggao perkisahaploinsufficienttumorsuppressorgenedosedeterminestumorsuppressiveversustumorpromotingpropertiesofperkinmelanoma AT chajewskiolgas perkisahaploinsufficienttumorsuppressorgenedosedeterminestumorsuppressiveversustumorpromotingpropertiesofperkinmelanoma AT wulawrence perkisahaploinsufficienttumorsuppressorgenedosedeterminestumorsuppressiveversustumorpromotingpropertiesofperkinmelanoma AT majsterekireneusz perkisahaploinsufficienttumorsuppressorgenedosedeterminestumorsuppressiveversustumorpromotingpropertiesofperkinmelanoma AT herlynmeenhard perkisahaploinsufficienttumorsuppressorgenedosedeterminestumorsuppressiveversustumorpromotingpropertiesofperkinmelanoma AT fuchssergey perkisahaploinsufficienttumorsuppressorgenedosedeterminestumorsuppressiveversustumorpromotingpropertiesofperkinmelanoma AT diehljalan perkisahaploinsufficienttumorsuppressorgenedosedeterminestumorsuppressiveversustumorpromotingpropertiesofperkinmelanoma |